18 results
Keyword crestor Remove keyword
-
List item
Referral: Crestor 5 mg
rosuvastatin calcium, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 21/04/2005, EC decision date: 09/08/2005, Last updated: 09/08/2005Crestor 5 mg … Commission final decision Overview Crestor (rosuvastatin calcium) is … Marketing Authorisation for Crestor (10 to 40 mg) was originally … -
List item
Referral: Crestor and associated names
rosuvastatin, Article 29 paediatrics
Status: European Commission final decision, opinion/position date: 30/06/2014, Last updated: 01/08/2014Crestor and associated names … cholesterol-lowering medicine Crestor to allow its use in children … aged between 6 to 10 years. Crestor and associated names are … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): rosuvastatin calcium
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseases
PIP number: Rosuvastatin (calcium), Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 24/11/2010, Last updated: 07/12/2009, Compliance check: V, 11/10/2013Key facts Crestor and associated names rosuvastatin … for rosuvastatin (calcium) (Crestor and associated names) (EMEA-000022-PIP01-07-M04 … rosuvastatin (calcium) (Crestor and associated names) (EMEA-000022-PIP01-07-M04 … -
List item
Press release: European Medicines Agency: Committee for Medicinal Products for Human Use 15-18 November 2004
Last updated: 18/11/2004Crestor … Community-wide referral procedure for Crestor (rosuvastatin) 5 mg from … differing views on whether Crestor 5 mg should be the recommended … -
List item
National expert: Rebeca de la Rosa Rodriguez, Spanish Agency of Medicines and Medical Devices (updated)
- Declaration of interests - 80.96 KB | PDF
- Curriculum Vitae - 18.7 KB | PDF
line NSCLC Rosuvastatin (Crestor) Heterozygous Familial Hypercholesterolemia … -
List item
Human medicine European public assessment report (EPAR): Repatha (updated)
Evolocumab, Dyslipidemias, Hypercholesterolemia
Date of authorisation: 17/07/2015, Revision: 17, Authorised, Last updated: 31/03/2021 -
List item
Human medicine European public assessment report (EPAR): Vosevi
Sofosbuvir, velpatasvir, voxilaprevi, Hepatitis C, Chronic
Date of authorisation: 26/07/2017,
, 
, Revision: 9, Authorised, Last updated: 08/06/2020
-
List item
Press release: European Medicines Agency: Committee for Medicinal Products for Human Use 18 – 21 April 2005
CHMP, Last updated: 21/04/2005a referral procedure for Crestor (rosuvastatin) 5mg from AstraZeneca … recommendations for the Crestor starting dose (5 mg or 10 … is favourable for either Crestor 5mg or 10mg as alternative … -
List item
Public data from Article 57 database
Last updated: 16/02/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 April 2014
European Medicines Agency, London, UK, from 22/04/2014 to 25/04/2014, Last updated: 09/08/2013 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 January 2014
European Medicines Agency, London, UK, from 20/01/2014 to 23/01/2014, Last updated: 09/08/2013 -
List item
News: 2012 annual report on EudraVigilance published
Last updated: 26/07/2013 -
List item
News: Annual report 2009 published: "Agency achieved very good results in one of the most challenging years in its history"
Last updated: 20/05/2010 -
List item
Workshop on identifying opportunities for 'big data' in medicines development and regulatory science
CCT Venue Plus, London, UK, from 14/11/2016 to 15/11/2016, Last updated: 04/01/2017 -
List item
Monthly reports of the CHMP Pharmacovigilance Working Party
Last updated: 31/12/2009 -
List item
CHMP: meeting archive 2001-2009
Last updated: 18/11/2013 -
List item
Annual reports and work programmes
Last updated: 15/06/2020 -
List item
CHMP: meeting archive 2013-2015
Last updated: 12/05/2016